Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

Mateos, María-Victoria; Martínez López, Joaquín; Rodriguez-Otero, Paula; Gonzalez-Calle, V.; González, Marta Sonia; Oriol, Albert; Gutiérrez, Norma C.; Ríos-Tamayo, Rafael; Rosiñol, Laura; Alvarez Rivas, Miguel Angel; Bargay, Joan; Gonzalez-Rodriguez, Ana Pilar; Alegre, Adrián; Escalante, F.; Íñigo Rodríguez, María Belén; de la Rubia Comos, Javier; Teruel, Ana Isabel; De Arriba, Felipe; Palomera, Luis; Hernández, Miguel T.; Lopez-Jimenez, J.; Reinoso-Segura, Marta; García Mateo, Aránzazu; Ocio, Enrique M.; Paiva, Bruno; Puig, Noemi; Cedena, M. Teresa; Bladé, Joan; Lahuerta, Juan José; San Miguel, Jesús F.

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

Early treatment of high-risk smoldering myeloma has been shown to delay progression to multiple myeloma (MM). We conducted this trial with curative intention using a treatment approach employed for newly diagnosed patients with MM.

Detalles Bibliográficos
Autores:	Mateos, María-Victoria, Martínez López, Joaquín, Rodriguez-Otero, Paula, Gonzalez-Calle, V., González, Marta Sonia, Oriol, Albert, Gutiérrez, Norma C., Ríos-Tamayo, Rafael, Rosiñol, Laura, Alvarez Rivas, Miguel Angel, Bargay, Joan, Gonzalez-Rodriguez, Ana Pilar, Alegre, Adrián, Escalante, F., Íñigo Rodríguez, María Belén, de la Rubia Comos, Javier, Teruel, Ana Isabel, De Arriba, Felipe, Palomera, Luis, Hernández, Miguel T., Lopez-Jimenez, J., Reinoso-Segura, Marta, García Mateo, Aránzazu, Ocio, Enrique M., Paiva, Bruno, Puig, Noemi, Cedena, M. Teresa, Bladé, Joan, Lahuerta, Juan José, San Miguel, Jesús F.
Tipo de recurso:	artículo
Fecha de publicación:	2024
País:	España
Institución:	Universidad Católica de Valencia San Vicente Mártir
Repositorio:	RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
Idioma:	inglés
OAI Identifier:	oai:riucv.ucv.es:20.500.12466/4688
Acceso en línea:	http://hdl.handle.net/20.500.12466/4688
Access Level:	acceso abierto
Palabra clave:	Myeloma Carfilzomib Lenalidomide Dexamethasone Transplant 32 Ciencias Médicas

id	ES_da032dcab01e1c17b9bfa0e788d4b37b
oai_identifier_str	oai:riucv.ucv.es:20.500.12466/4688
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd MaintenanceMateos, María-VictoriaMartínez López, JoaquínRodriguez-Otero, PaulaGonzalez-Calle, V.González, Marta SoniaOriol, AlbertGutiérrez, Norma C.Ríos-Tamayo, RafaelRosiñol, LauraAlvarez Rivas, Miguel AngelBargay, JoanGonzalez-Rodriguez, Ana PilarAlegre, AdriánEscalante, F.Íñigo Rodríguez, María Belénde la Rubia Comos, JavierTeruel, Ana IsabelDe Arriba, FelipePalomera, LuisHernández, Miguel T.Lopez-Jimenez, J.Reinoso-Segura, MartaGarcía Mateo, AránzazuOcio, Enrique M.Paiva, BrunoPuig, NoemiCedena, M. TeresaBladé, JoanLahuerta, Juan JoséSan Miguel, Jesús F.MyelomaCarfilzomibLenalidomideDexamethasoneTransplant32 Ciencias MédicasEarly treatment of high-risk smoldering myeloma has been shown to delay progression to multiple myeloma (MM). We conducted this trial with curative intention using a treatment approach employed for newly diagnosed patients with MM.20242024-10-2820242024-07-2220242024-07-22journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12466/4688reponame:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártirinstname:Universidad Católica de Valencia San Vicente MártirInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:riucv.ucv.es:20.500.12466/46882026-06-19T08:32:07Z
dc.title.none.fl_str_mv	Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
title	Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
spellingShingle	Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance Mateos, María-Victoria Myeloma Carfilzomib Lenalidomide Dexamethasone Transplant 32 Ciencias Médicas
title_short	Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
title_full	Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
title_fullStr	Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
title_full_unstemmed	Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
title_sort	Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
dc.creator.none.fl_str_mv	Mateos, María-Victoria Martínez López, Joaquín Rodriguez-Otero, Paula Gonzalez-Calle, V. González, Marta Sonia Oriol, Albert Gutiérrez, Norma C. Ríos-Tamayo, Rafael Rosiñol, Laura Alvarez Rivas, Miguel Angel Bargay, Joan Gonzalez-Rodriguez, Ana Pilar Alegre, Adrián Escalante, F. Íñigo Rodríguez, María Belén de la Rubia Comos, Javier Teruel, Ana Isabel De Arriba, Felipe Palomera, Luis Hernández, Miguel T. Lopez-Jimenez, J. Reinoso-Segura, Marta García Mateo, Aránzazu Ocio, Enrique M. Paiva, Bruno Puig, Noemi Cedena, M. Teresa Bladé, Joan Lahuerta, Juan José San Miguel, Jesús F.
author	Mateos, María-Victoria
author_facet	Mateos, María-Victoria Martínez López, Joaquín Rodriguez-Otero, Paula Gonzalez-Calle, V. González, Marta Sonia Oriol, Albert Gutiérrez, Norma C. Ríos-Tamayo, Rafael Rosiñol, Laura Alvarez Rivas, Miguel Angel Bargay, Joan Gonzalez-Rodriguez, Ana Pilar Alegre, Adrián Escalante, F. Íñigo Rodríguez, María Belén de la Rubia Comos, Javier Teruel, Ana Isabel De Arriba, Felipe Palomera, Luis Hernández, Miguel T. Lopez-Jimenez, J. Reinoso-Segura, Marta García Mateo, Aránzazu Ocio, Enrique M. Paiva, Bruno Puig, Noemi Cedena, M. Teresa Bladé, Joan Lahuerta, Juan José San Miguel, Jesús F.
author_role	author
author2	Martínez López, Joaquín Rodriguez-Otero, Paula Gonzalez-Calle, V. González, Marta Sonia Oriol, Albert Gutiérrez, Norma C. Ríos-Tamayo, Rafael Rosiñol, Laura Alvarez Rivas, Miguel Angel Bargay, Joan Gonzalez-Rodriguez, Ana Pilar Alegre, Adrián Escalante, F. Íñigo Rodríguez, María Belén de la Rubia Comos, Javier Teruel, Ana Isabel De Arriba, Felipe Palomera, Luis Hernández, Miguel T. Lopez-Jimenez, J. Reinoso-Segura, Marta García Mateo, Aránzazu Ocio, Enrique M. Paiva, Bruno Puig, Noemi Cedena, M. Teresa Bladé, Joan Lahuerta, Juan José San Miguel, Jesús F.
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv	Myeloma Carfilzomib Lenalidomide Dexamethasone Transplant 32 Ciencias Médicas
topic	Myeloma Carfilzomib Lenalidomide Dexamethasone Transplant 32 Ciencias Médicas
description	Early treatment of high-risk smoldering myeloma has been shown to delay progression to multiple myeloma (MM). We conducted this trial with curative intention using a treatment approach employed for newly diagnosed patients with MM.
publishDate	2024
dc.date.none.fl_str_mv	2024 2024-10-28 2024 2024-07-22 2024 2024-07-22
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	http://hdl.handle.net/20.500.12466/4688
url	http://hdl.handle.net/20.500.12466/4688
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir instname:Universidad Católica de Valencia San Vicente Mártir
instname_str	Universidad Católica de Valencia San Vicente Mártir
reponame_str	RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
collection	RIUCV. Repositorio de la Universidad Católica de Valencia San Vicente Mártir
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869421489397170176
score	15,81155

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

Similares en LA Referencia